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vidence for an Increased Rate of Cardiovascular
vents in Patients With Primary Aldosteronism
aul Milliez, MD,* Xavier Girerd, MD, PHD,† Pierre-Franc¸ois Plouin, MD,‡ Jacques Blacher, MD, PHD,§
ichel E. Safar, MD,§ Jean-Jacques Mourad, MD, PHD
aris and Bobigny, France
OBJECTIVES The aim of this report was to show that the rate of cardiovascular events is increased in
patients with either subtype of primary aldosteronism (PA).
BACKGROUND Primary aldosteronism involves hypertension (HTN), hypokalemia, and low plasma renin.
The two major PA subtypes are unilateral aldosterone-producing adenoma (APA) and
bilateral adrenal hyperplasia.
METHODS During a three-year period, the diagnosis of PA was made in 124 of 5,500 patients referred
for comprehensive evaluation and management. Adenomas were diagnosed in 65 patients and
idiopathic hyperaldosteronism in 59 patients. During the same period, clinical characteristics
and cardiovascular events of this group were compared with those of 465 patients with
essential hypertension (EHT) randomly matched for age, gender, and systolic and diastolic
blood pressure.
RESULTS A history of stroke was found in 12.9% of patients with PA and 3.4% of patients with EHT (odds
ratio [OR] 4.2; 95% confidence interval [CI] 2.0 to 8.6]). Non-fatal myocardial infarction was
diagnosed in 4.0% of patients with PA and in 0.6% of patients with EHT (OR  6.5; 95% CI
1.5 to 27.4). A history of atrial fibrillation was diagnosed in 7.3% of patients with PA and 0.6%
of patients with EHT (OR  12.1; 95% CI 3.2 to 45.2). The occurrence of cardiovascular
complications was comparable in both subtypes of PA.
CONCLUSIONS Patients presenting with PA experienced more cardiovascular events than did EHT patients
independent of blood pressure. The presence of PA should be detected, not only to determine
the cause of HTN, but also to prevent such complications. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.0151243–8) © 2005 by the American College of Cardiology Foundation
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Trimary aldosteronism (PA), resulting from an adrenocor-
ical adenoma, is a potentially curable form of hypertension
HTN). The two major subtypes of PA are unilateral
ldosterone-producing adenoma (APA), or Conn’s ade-
oma, and bilateral adrenal hyperplasia (idiopathic hyper-
ldosteronism) (1). Prevalence estimates for PA vary from
.5% to 2% of the hypertensive population (2,3), but recent
See page 1249
tudies have reported increased values (4). Initially, HTN
ssociated with PA was considered mild and readily con-
rolled as well as rarely complicated (5). However, several
uthors reported series or case reports of PA with severe to
alignant HTN, or with marked target organ damage
ffecting the heart, the carotid artery, or the kidney (6–8).
ther studies noted an increased prevalence of cerebrovascular
iseases (9–11) in PA. Rossi et al. (12) reported that in patients
ith PA, the excess aldosterone could be associated with a
ressure-independent remodeling of the left ventricle. Surpris-
From the *Department of Cardiology, Lariboisière Hospital, Paris, France;
Department of Endocrinology, Pitié-Salpêtrière Hospital, Paris, France; ‡Depart-
ent of Hypertension, Georges Pompidou Hospital, Paris, France; §Diagnosis
enter, Hôtel-Dieu, Paris, France; and Department of Internal Medicine, Avicenne
ospital, Bobigny, France.d
Manuscript received March 27, 2004; revised manuscript received December 20,
004, accepted January 4, 2005.ngly, despite this cardiac remodeling, few cardiac complica-
ions (myocardial infarction [MI], arrhythmias) have been
oted in association with PA. Two case reports described
ssociation of atrial fibrillation (AF) (13) and ventricular
brillation (14) with PA. Most recently, Nishimura et al. (11)
ound only one patient in their study of PA with associated
oronary artery disease.
The aim of this investigation was to conduct a case-
ontrol study to test the hypothesis that the rate of cardio-
ascular complications is increased in a large group of
atients with either subtype (APA or bilateral adrenal
yperplasia) of PA.
ETHODS
verall patient population and PA diagnostic workup. From
anuary 1997 to December 1999, approximately 5,500
ypertensive patients were referred to the Department of
ypertension of Broussais Hospital (Paris, France). This
epartment was composed of three units: one was devoted
o consultation and the two others specialized in either
ormonal or hemodynamic evaluations. In the three units,
he same comprehensive evaluation and management was
erformed, using the same investigation algorithm and the
ame computerized program databank, ARTEMIS (15).
his database has been used since 1975 and was initially
esigned to replace the traditional handwritten medical
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anagement system in order to provide additional informa-
ion (complementary patient interrogation, biological or
adiologic investigations, and so on). Answer rates to 12
andatory questions regarding history and examination at
rst visit were 95% in 19,601 records (15). All patients in
he study underwent a standardized protocol to measure
lood pressure (BP) and biological and hormonal parame-
ers. Standard BP tests were performed using mercury
phygmomanometer in the supine position after 10 min
est. One physician performed three consecutive measure-
ents and the average of the last two measurements was
hen recorded. Semiautomatic noninvasive measurements of
P were performed by the Dinamap 1846SX device (Cri-
ikon Inc., Tampa, Florida). Ten automatic measurements
ere recorded on a printer before the standard measure-
ent. The average of the last five measurements was
onsidered as the value of BP obtained with this device.
Medications were withdrawn approximately two weeks be-
ore the evaluation (for spironolactone, at least six weeks) (16).
n the presence of severe or symptomatic hypertension, the
orkup was made under antihypertensive medications known
s poorly affecting measurements of plasma renin and aldoste-
one (16). In the case of suspected PA (i.e., low plasma renin
oncentration, high rates of plasma and urinary aldosterone,
nd elevated plasma aldosterone to plasma renin ratio [ARR]),
atients underwent: 1) a suppression test that consisted of the
easurement of plasma renin and aldosterone levels before and
fter the oral administration of 1 mg/kg weight of the con-
erting enzyme inhibitor captopril (17), and 2) a computed
omographic (CT) scanning of the adrenal glands (3-mm
lices) (16). In 15 subjects with equivocal CT findings, adrenal
enous sampling was performed to evaluate whether one or
oth adrenal glands were producing aldosterone (18).
tudy population. During this period, the diagnosis of PA
as made in 124 patients. Adenomas (n  65) were
iagnosed when an adrenal tumor was observed by CT scan,
ogether with evidence of functional autonomy or lateral-
zation of adrenal aldosterone secretion. In patients with a
amily history of hypertension, genetic tests were performed
Abbreviations and Acronyms
AF  atrial fibrillation
APA  aldosterone-producing adenoma
ARR  aldosterone to renin ratio
BP  blood pressure
CI  confidence interval
CT  computed tomographic
ECG  electrocardiogram/electrocardiographic
EHT  essential hypertension
HTN hypertension
LVH  left ventricular hypertrophy
MI  myocardial infarction
OR  odds ratio
PA  primary aldosteronismo exclude inherited forms of hyperaldosteronism (mainly olucocorticoid-suppressible hyperaldosteronim) (19). An
denoma was confirmed surgically in 58 patients, but 7
ther patients did not accept surgery and were treated by the
ldosterone antagonist spironolactone, alone or associated
ith various other antihypertensive drugs. Idiopathic hyper-
ldosteronism was diagnosed in 59 patients whose CT scans
howed unilateral or bilateral adrenal hyperplasia without
ny significant adenoma. These patients were treated with
ntihypertensive medication, mainly based on spironolac-
one (20). During the follow-up of this group (mean
ollow-up 13.6  0.4 months), no change in diagnosis was
eported and no patient experienced any cardiovascular
omplication. At the end of the follow-up, systolic BP was
37  13 mm Hg and diastolic BP was 84  9 mm Hg.
During the same period, the diagnosis of essential hyper-
ension was made using the same diagnostic work-up in
pproximately 4,000 patients. For each case of PA, the
oftware (15) randomly extracted from the database patients
ith essential hypertension matched for age (5 years),
ender, and systolic and diastolic BP (2 mm Hg), on the
heoretical basis of one case for four controls.
Finally, the clinical characteristics and cardiovascular
vents of the group of patients with PA were compared with
hose of 465 matched patients who underwent the same
nitial clinical and biological evaluation that lead to the
iagnosis of essential hypertension (EHT). Criteria for
uling out secondary forms of hypertension involved con-
tant measurements of plasma renin and aldosterone and
uplex ultrasound of the renal arteries.
The medical records of the participants were reviewed
ndependently by two investigators (P.M. and J.J.M.), who
ssessed whether any of the following major clinical events
ad occurred: MI, stroke, cardiac arrhythmias (originating
rom either atrium or ventricle), as described elsewhere (21).
rrhythmias were counted as such when episodes of re-
ented palpitations were documented by either conventional
2-lead surface electrocardiogram (ECG) or 24-h ECG
ecording (Holter). Criteria for left ventricular hypertrophy
LVH) either by ECG or echocardiography have been
eported elsewhere (22). Silent myocardial ischemia noted
n classical ECGs, stable or transient angina pectoris,
typical chest pain, intermittent symptoms possibly related
o transient ischemic attacks were excluded from the statis-
ical evaluation. All these parameters were collected at entry
nd stored in the database before any diagnosis of PA. The
vents were finally confirmed at the end of the diagnostic
orkup by a committee composed of three physicians inde-
endent of the department and blinded for the diagnosis.
tatistical analysis. Selection of the controls was comput-
rized on a large database, ARTEMIS (15), and was
utomatically and randomly performed in respect to our
riteria (age, gender, and BP) up to four subjects, if existing
n the database. This “blinded” procedure limited potential
election bias but resulted in the absence of knowing which
ontrols were allocated to which case, that is to say, that
nly non-paired procedures could be used for data analysis.
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April 19, 2005:1243–8 Cardiovascular Events and Primary AldosteronismAll results are expressed as a mean values  SD. Univar-
ate analysis allowed screening of potential predictors of PA.
he Student t test was used for a quantitative variable and
hi-square or Fisher exact test for qualitative or semiquan-
itative variables. The risk of cardiovascular complications
as expressed in terms of odds ratio (OR)95% confidence
nterval (CI). In multiparametric logistic regression analysis,
onsidering a history of MI, stroke, or AF as response
ariables, we included in the model factors significantly (p
.05) associated in univariate analysis with those three
arameters. No parameter was forced in the model. Age,
ystolic BP, diastolic BP, plasma glucose, potassium, and
otal cholesterol were expressed as quantitative variables,
hereas gender, smoking, PA, and EHT were expressed as
ummy variables. Because the study was begun in 1997,
ow-density lipoprotein and high-density lipoprotein cho-
esterol, glycated hemoglobin, or other biological parame-
ers were excluded from the study because they were not
ystematically determined in each individual. Analyses were
erformed with SPSS software version 11.0 (SPSS Inc.,
hicago, Illinois) under Windows XP (Microsoft, Red-
ond, Washington). All the Student t tests were general
ormal non-paired tests with a 0.05 significance level.
ESULTS
linical characteristics of the population. Clinical and
iological data of the PA patients and their EHT controls
re summarized in Tables 1 and 2. By definition, cases and
ontrols were similar in age (52 10 years), gender (67% vs.
3% male, respectively), systolic BP (176  23 mm Hg vs.
74  20 mm Hg, respectively) and diastolic BP (107  14
m Hg vs. 106  14 mm Hg, respectively). Of the
emaining parameters, plasma total cholesterol was signifi-
antly higher in the EHT group (5.9  1.1 mmol/l vs. 5.4 
.9 mmol/l in the PA group; p  0.0004). Past or current
moking habits and serum glucose did not differ.
As expected, patients with PA had lower serum potas-
ium than controls (3.5  0.3 mmol/l vs. 4.4  0.3 mmol/l,
espectively; p  0.0001), whereas serum creatinine was
omparable (92  24 mol/l vs. 87  36 mol/l respec-
ively, p  NS). Similarly, urinary potassium, plasma
ldosterone, aldosterone/renin ratio, and urinary aldoste-
one were significantly higher in the PA group than in the
HT controls (Table 2).
ate of cardiovascular events. A history of stroke was
eported in 16 patients with PA and in 16 patients with
HT (12.9% vs. 3.4%; OR  4.2; 95% CI 2.0 to 8.6). The
tiology was clearly ischemic in 11 of the PA group and in
patients with EH (Table 3). Univariate analysis indicated
hat the group of patients with a history of stroke was older
p  0.0005) and had a higher systolic BP (p  0.02) and
erum creatinine (p  0.005). In addition, the prevalence of
iabetes, hypercholesterolemia, and ECG left ventricular
ypertrophy was higher in patients with a history of stroke
hen compared with subjects free from cerebrovascular ovents (p  0.0005, p  0.0005, and p  0.002, respec-
ively). Multivariate analysis indicated that parameters in-
ependently associated with a history of stroke were age (p
0.004), Sokolow-Lyon index (p  0.003), and the
resence of PA (p  0.0003).
A history of non-fatal MI was diagnosed in five patients
ith PA and in three patients with EHT (4.0% vs. 0.6%;
R  6.5; 95% CI 1.5 to 27.4). Patients with a history of
I were significantly older (p  0.01) and were more likely
o have PA (p  0.005). These two parameters were still
ndependently associated with a history of MI in multivar-
ate analysis (p  0.008 and p  0.005, respectively).
A history of AF was diagnosed in 10 patients with PA
nd in 3 patients with EHT (7.3% versus 0.6%; OR 12.1;
5% CI 3.2 to 45.2). In multivariate analysis, including
arameters significantly associated with the presence of AF,
re three remaining factors: age (p  0.005), duration of
ypertension (p  0.01), and the presence of PA (p 
.001). All of these factors are independently associated
ith a history of AF.
Electrocardiographic as well as echocardiographic LVH
as significantly more frequent in the PA group than in the
HT group (32% vs. 14% [p  0.001] for ECG LVH,
espectively, and 34% vs. 24% [p  0.01] for echocardiog-
aphy, respectively).
omparison between subtypes of PA. Of the 124 patients
ith PA, 65 had adenomas and 59 had bilateral adrenal
yperplasia. The two subgroups were similar in age, BP,
ardiovascular risk factors, serum potassium, and prevalence
f cardiovascular events (data not shown). However, APA
ad a more pronounced hormonal profile of hyperaldoste-
onism than hyperplasia, with a higher serum aldosterone
360  193 pg/ml vs. 259  137 pg/ml, respectively; p 
.01) and a higher aldosterone/renin ratio (114  103 vs.
2  67, respectively; p  0.01).
Fifty-eight patients (out of 65 with adenomas) underwent
urgery. Although almost all patients had improved control
f BP after surgery, long-term (mean follow-up 13.6  0.4
onths) cure rate (BP140/90 mm Hg without drug) with
nilateral adrenalectomy for APA was 43% in this study (25
able 1. Clinical Characteristics and Risk Factors Parameters of
rimary Aldosteronism Patients and Controls
Primary
Aldosteronism
(n  124)
Essential
Hypertension
(n  465)
p
Value
ge (yrs) 52  10 52  10 NS
en/women (%) 67/33 63/37 NS
BP (mm Hg) 176  23 174  20 NS
BP (mm Hg) 107  14 106  14 NS
eart rate (beats/min) 72  8 72  10 NS
urrent or past smokers (%) 42 44 NS
erum glucose (mmol/l) 6.0  1.3 5.9  1.9 NS
otal cholesterol (mmol/l) 5.4  0.9 5.9  1.1 0.0004
alues expressed as mean  SD.
DBP  diastolic blood pressure; SBP  systolic blood pressure.f 58). Seventeen patients were normalized (BP 140/90
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Cardiovascular Events and Primary Aldosteronism April 19, 2005:1243–8m Hg under drug treatment) and 16 patients were
ncontrolled at the end of the follow-up (mean BP 153 
/91  2 mm Hg). All patients were normokaliemic after
urgery.
ISCUSSION
his study has shown that patients presenting with PA from
ither aldosterone-producing adenoma or bilateral adrenal
yperplasia subtype have a significantly higher rate of
ardiovascular events than the matched EHT patients. To
ur knowledge, this investigation is the first to indicate that
oth subtypes of PA are substantially and equally compli-
ated, particularly owing to an unusual rate of cardiovascular
omplications including arrhythmia.
ate of cardiovascular events in patients with PA. In the
ast, experimental models of hypertension have shown that
xcess aldosterone induces severe injury in the heart, brain,
nd kidneys independent of BP level and that pharmaco-
ogical antagonists of aldosterone or adrenalectomy mark-
dly reduced myocardial injury, cerebral hemorrhage, and
enal vascular disease (see review in Rocha and Stier [23]).
n clinical studies (5,9–11), no comparable results have been
eported, either because bilateral adrenal hyperplasia was
xcluded from the analysis (6,9,11) or the investigation did
ot include a control population (10,11). In the work by
akeda et al. (9), which constituted the largest case-control
tudy of PA, EHT controls were matched for age and
ender, but not for BP level. Thus, the role of high BP on
he mechanism of cardiovascular complications could not be
xcluded.
In our institution, we performed a specific workup to spot
atients having secondary forms of hypertension. Hence, all
Table 2. Biological Characteristics of Primary
Primary Aldo
(n  1
Serum potassium (mmol/l) 3.5 
Serum creatinine (mol/l) 92 
Urinary potassium (mmol/24 h) 80 
Active plasma renin (pg/ml) 4.7 
Plasma aldosterone (pg/ml) 374 
Aldosterone/renin ratio 94 
Urinary aldosterone (g/24 h) 34 
Values expressed as mean  SD.
Table 3. Rate of Cardiovascular Events and C
Patients and Controls
Primary
Aldosteronism
(n  124)
Stroke (%) 12.9
Myocardial infarction (%) 4.0
Atrial fibrillation (%) 7.3
Echocardiographic LVH (%) 34
Electrocardiographic LVH (%) 32*Fisher exact test.
CI  confidence interval; LVH  left ventricular hypertrophy.atients were diagnosed with the same hormonal and radio
maging protocols (CT scanning and in case of doubt,
drenal venous sampling) (15). As a consequence, between
anuary 1997 and December 1999, all of the 5,500 patients
ere studied consecutively and homogeneously, and the 124
A cases were diagnosed and cured by the same physicians
uring this period. The BP measurements were made using
he same methodology in the different units of the depart-
ent. The selection of the subjects as well as the statistical
valuation was performed from the same database in order
o minimize any selection bias. Although no 24-h ambula-
ory BP measurements were constantly performed, it ap-
ears that relatively severe hypertension was found in all
atients with systolic BP of 176  23 mm Hg and diastolic
P of 107  14 mm Hg and a predominance of younger
ales (52  10 years; 67%). These findings agree with
revious reports that emphasized such elevated BP (2,3,6).
nterestingly, no predominance of one subtype of PA was
ound (65 APA vs. 59 hyperplasia). Hence, bilateral adrenal
yperplasia should not be considered as a minor form of PA.
Our group was aware of the risk of inflating the diagnosis
f PA by considering only the ARR level (24). We con-
tantly required an elevated plasma aldosterone level before
onsidering the ARR as abnormal. Applying this strict
rotocol together with rigorous conditions for measure-
ents of plasma renin and aldosterone may explain the
mall proportion of normokalemic PA patients in this
ohort (3 of 124) by contrast with others (25).
In the present study, both patients with documented
PA and idiopathic aldosteronism were considered for
omparing the rate of cardiovascular events to matched
HT patients. Furthermore, it appeared relevant to note
steronism Patients and Controls
nism Essential Hypertension
(n  465) p Value
4.4  0.3 0.0001
87  36 NS
63  25 0.0003
17.5  15.3 0.0001
116  60 0.0001
11  10 0.0001
16  6 0.01
c Structure in Primary Aldosteronism
Essential
Hypertension
(n  465)
Odds Ratio
(95% CI) p Value
3.4 4.2 (2.0–8.6) 0.001
0.6 6.5 (1.5–27.4) 0.005*
0.6 12.1 (3.2–45.2) 0.0001*
24 1.6 (1.1–2.5) 0.01
14 2.9 (1.8–4.6) 0.001Aldo
stero
24)
0.3
24
37
2.6
174
90
17ardia
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April 19, 2005:1243–8 Cardiovascular Events and Primary Aldosteronismhether or not this rate differed between both subtypes of
A. We found higher percentage of strokes (either hemor-
hagic or infarction) in our PA population than in controls
12.9 % vs. 3.4%; p 0.001), confirming all previous studies
10,11). However, we observed an unusual rate of cardiac
omplications in PA patients. Myocardial infarction was
ignificantly more frequent in PA group than in controls
4.0% vs. 0.6%; p  0.005). Similarly, an impressive rate of
F was found in patients with PA (7.3% vs. 0.6% in PA and
HT patients, respectively; p  0.0001). This frequency of
ardiac and arrhythmic events had never been previously
eported. To our knowledge, only two case reports noted
ssociation of cardiac arrhythmias and PA (AF [13] and
entricular fibrillation [14]). Regarding the incidence of MI,
akeda et al. (9) found identical rates of MI in PA and
HT populations.
elative contribution of BP and hyperaldosteronism to
ardiovascular complications and limitations of the
tudy. In this investigation, both patients with documented
PA and idiopathic aldosteronism were matched to EHT
or gender, age, and most importantly, BP. Hence, within
he limitations of the methodology of this case-control
tudy, the rate of cardiovascular events has been studied
ndependently from BP level, suggesting that aldosterone
lone has a specific role in the occurrence of cardiovascular
omplications. The results of multiple regression analysis
onfirm this possibility and, furthermore, do not suggest
hat hypokalemia played a crucial role in the pathophysiol-
gy of such complications.
Hypertensive heart disease associated with LVH is
nown to be associated with an increase of plasma aldoste-
one and an increase of cardiac collagen volume fraction and
brosis, as derived from experimental and clinical works
26,27). Aldosterone excess and LVH are known to inde-
endently increase fibrosis within the heart (28–30). The
nderlying mechanisms are incompletely understood; re-
ently, the role of endothelin pathway had been highlighted
31). In our study, PA patients had, independent of BP, a
igher rate of LVH than the EHT controls. Thus it seems
ogical to suggest that aldosterone and/or cardiac fibrosis might
lay a role on the occurrence of LVH and possible resulting
ardiac complications (28,29). Minor or no (32) evidence of
eft ventricular dysfunction has been reported in PA.
Regarding arrhythmias, experimental models of conges-
ive heart failure have shown that cardiac fibrosis might be
t the origin of these alterations. Cardiac fibrosis often
redominate in the left atrium and may be mediated more
y the renin-angiotensin pathway than by mechanical
tretch (33–35). Recently, the Randomized ALdactone
valuation Study (RALES) demonstrated that in patients
ith congestive heart failure, adjunction of spironolactone
o usual medical therapy significantly reduced both cardiac
ortality and sudden cardiac death, which is known to be
artly due to arrhythmic disorders (36,37). Thus, the weight
f evidence suggests that excess aldosterone might be a risk
actor for arrhythmic disorders occurring either via LVH or viaardiac fibrosis or a combination of both (38,39). In the
articular case of AF, an increased incidence of reentry mech-
nisms has been also reported (38–40). In practice, such
linical pictures raise the issue of differentiating strokes occur-
ing in PA patients with and without AF, the latter potentially
aused by aldosterone-induced local microangiopathy. These
iagnoses are difficult to perform in clinical practice, also
ecause the role of aldosterone-induced hemorrhagic mecha-
isms cannot be excluded in PA patients (40,41).
Although LVH and myocardial fibrosis would explain the
ncrease in AF, it may be more difficult to explain the
ncrease in MI and stroke on this basis. However, it has
een shown that aldosterone may be associated with endo-
helial dysfunction independent of BP and to produce
icrovascular inflammation in the brain but also the myo-
ardium (23). On the other hand, recent studies have
oticed that chronic excess aldosterone experimentally pro-
uces an increase of aortic stiffness, independent of BP. The
ncreased stiffness is reversed under administration of the
pecific alosterone antagonist eplerenone (42). Both in
ubjects with hypertension (43) and in subjects with con-
estive heart failure (44), a positive, significant, and inde-
endent association has been reported between high plasma
ldosterone and high arterial stiffness. Increased arterial
tiffness, an important feature of hyperaldosteronism, is
nown to be a strong and independent predictor of MI (21).
Finally, the interpretation of the interactions among
yperaldosteronism, BP, and cardiovascular complications
hould be done cautiously because this case-control study is
etrospective with potential selection bias. Furthermore,
ecause of the design of our study with computerized and
andom selection of the controls, only non-paired proce-
ures were used for data analysis. Time-dependent relation-
hip should be important to evaluate in order to establish
ause to effect links between PA and the occurrence of
ardiovascular events. Nevertheless, for ethical reasons, such
prospective study should be difficult to conduct.
In conclusion, the present study has shown that patients
resenting PA experienced more cardiovascular events than
id EHT controls, independent of BP. Cardiovascular
omplications (including arrhythmic) are significantly in-
reased in both subtypes of PA. Consequently, PA should
e more carefully detected in order to avoid such compli-
ations.
eprint requests and correspondence: Dr. Michel Safar, Centre
e Diagnostic, Hôtel-Dieu, 1, Place du Parvis Notre-Dame,
5181 Paris Cedex 04, France. E-mail: michel.safar@htd.aphp.fr.
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